CLSN News and Press, Celsion Corporation

Celsion ( NASDAQ: CLSN ) announced Monday its decision to change company's name to Imunon. The new name of clinical-stage drug development company is claimed to outline the "evolution of its business and its commitment to developing cutting-edge immunotherapies and next-ge...

New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings a...

Celsion ( NASDAQ: CLSN ) said on Thursday that additional data from its completed proof-of-concept mouse challenge study confirmed that its DNA-based placcine vaccine can produce robust levels of ImmunoglobulinG, neutralizing antibodies, and T-cell responses. The additiona...

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update...

Celsion Corporation (CLSN) Q2 2022 Earnings Conference Call August 15, 2022, 11:00 am ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne Le Goff - President & CEO Jeffrey Church - CFO Nicholas Bo...

Celsion press release ( NASDAQ: CLSN ): Q2 GAAP EPS of -$0.87. Revenue of $0.13M (flat Y/Y). The company ended the second quarter of 2022 with $48.1M in cash, investments, restricted cash, and accrued interest receivable. Coupled with future planned sales of the co...

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-develo...